Biotech Drug Delivery Systems - Key Company Intelligence & Market Outlook to 2012

Abstract

The two major problems for biotech drugs are their mode of delivery and relative instability. The majority of delivery methods for biological drugs involve injection, which is not necessarily ideal for most indications. As the biotech sector starts to heat up, the industry has started to look for new ways of delivering these highly successful drugs.

Two main themes that run through this report: patent loss for leading biotech drugs and the use of technology to enable newer drugs to be more effective. Central to both of these matters is the perception that new drugs rely on old delivery technologies to get past the regulatory authorities, whereas old drugs look to new techniques to survive. This report will examine and challenge that approach; visiongain suggests that pharmaceutical companies should look to new drug delivery systems as they develop new drugs, in order to make the most out of these technologies.

• Revenue forecasts for the biological drug delivery market
• Drivers and restraints of the market are identified and discussed
• An analysis of strengths, weaknesses opportunities and threats (SWOT) for the biological drug delivery market
• Future targets for drug delivery technology
• Summaries and analysis of the leading drug delivery companies and their pipelines
• Special focus on oral drug delivery and injection technologies
• An assessment of potential advances, including the challenge of RNA delivery

In stark contrast to the pharmaceutical market as a whole, which is exhibiting single digit growth, the biotech market is still growing significantly with constantly innovative products. The proven methods, such as intravenous infusion and intra-muscular/subcutaneous injection, have remained the standard mode of administration, whereas the novelty has come from new improved protein therapeutics. This situation may be set to change, however, as key products lose patent protection and the market for some biotech drugs becomes more congested.

The report answers key questions such as:

• Which drug delivery companies are likely to be at the forefront of Biotech launches?
• What will be the revenue impact of altering the drug delivery method of patented drugs?
• What will be the revenue in 2012 for biotech drugs using novel drug delivery methods?
• How will the regulatory rulings involving Biosimilar products effect innovation?
• Understand the effect of nanotechnology on the drug delivery methods of biotech drugs

This report includes visiongain' s predictions of the Top 10 drugs most likely to be targeted for Biogenerics and the impact on revenue to their current manufacturers.

With Wyeth and AstraZeneca this week signing technology deals, this market is hot. This report will keep you up to date and fully informed of the latest developments in your marketplace.